The Evolving Landscape of Sickle Cell Disease Treatment Cristina Ferrario ++++

https://www.medscape.com/viewarticle/evolving-landscape-sickle-cell-disease-treatment-2026a1000k5y STOCKHOLM — The treatment landscape for sickle cell disease (SCD) is evolving rapidly, with new drugs and gene-based therapies offering a realistic prospect of cure. For most patients, however, particularly in low- and middle-income countries (LMICs), access to these innovations remains a major challenge if not a distant dream. The present and future of SCD treatment were explored in depth at an educational session during the European Hematology Association 2026 Congress. Erfan Nur, MD, PhD, clinical hematologist, Amsterdam University Medical Center, chaired the session. Are Artificially Sweetened Beverages Linked to Liver Cancer? Tara Haelle https://www.medscape.com/viewarticle/are-artificially-sweetened-beverages-linked-liver-cancer-2026a1000kav June 16, 2026 Drinking artificially sweetened beverages was not associated with an increased risk for liver cancer, but consumption of sugar-sweetened beverages (SSBs) was linked to two types of liver cancer, a new study found. Surveillance Colonoscopy Offers Limited Value After Age 75 Diana Swift https://www.medscape.com/viewarticle/surveillance-colonoscopy-offers-limited-value-after-age-75-2026a1000kaj June 16, 2026 In adults aged 75 years or older, the risk for death from causes other than colorectal cancer (CRC) greatly exceeded the 10-year risk for diagnosis or CRC-specific death, regardless of previous adenoma diagnosis, a large study of US veterans found. Talquetamab Combinations Show Survival Benefit in r/r Myeloma Randy Dotinga https://www.medscape.com/viewarticle/talquetamab-combinations-show-survival-benefit-r-r-myeloma-2026a1000k6r June 16, 2026 Combinations of the bispecific antibody talquetamab and daratumumab — with or without pomalidomide — outperformed standard therapy in patients with relapsed or refractory (r/r) multiple myeloma, according to an interim analysis of the randomized phase 3 trial MonumenTAL-3.